Modulating the DNA Damage Response to Improve Treatment Response in Cervical Cancer. Issue 9 (September 2017)

• Record Type: Journal Article
• Authors: Cossar, L.H.; Schache, A.G.; Risk, J.M.; Sacco, J.J.; Jones, N.J.; Lord, R.
• Is Part Of: Clinical oncology. Volume 29:Issue 9(2017)
• Page Start: 626
• Page End: 634
• Publication Date: 2017-09
• Subjects: Cervical cancer -- DNA damage response -- HPV; Oncology -- Periodicals; Tumors -- Periodicals; Cancer -- Treatment -- Periodicals; Radiotherapy -- Periodicals; Neoplasms -- Periodicals; Cancer -- Radiotherapy; Cancer -- Treatment; Oncology; Medical radiology; Radiotherapy; Tumors; Electronic journals; Periodicals; 616.994
• DOI: 10.1016/j.clon.2017.03.002
• Languages: English
• ISSNs: 0936-6555

Abstract

Abstract: Cervical cancer is the fourth most common cause of cancer-related death in women worldwide and new therapeutic approaches are needed to improve clinical outcomes for this group of patients. Current treatment protocols for locally advanced and metastatic disease consist of ionising radiation and chemotherapy. Chemoradiation induces cytotoxic levels of DNA double-strand breaks, which activates programmed cell death via the DNA damage response (DDR). Cervical cancers are unique given an almost exclusive association with human papillomavirus (HPV) infection; a potent manipulator of the DDR, with the potential to alter tumour sensitivity to DNA-damaging agents and influence treatment response. This review highlights the wide range of therapeutic strategies in development that have the potential to modulate DDR and sensitise cervical tumours to DNA-damaging agents in the context of HPV oncogenesis. Highlights: Locally advanced/advanced cervical cancer is treated with DNA damaging agents. HPV manipulates the DNA damage response and may affect treatment sensitivity. Therapies which modulate the DNA damage response are in development. Such therapies may increase treatment response and improve clinical outcomes.